HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy: Difference between revisions
| [pending revision] | [pending revision] |
| Line 52: | Line 52: | ||
==Gene Rearrangements== | ==Gene Rearrangements== | ||
No recurrent gene rearrangements have been described. | |||
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span> | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 295: | Line 295: | ||
|- | |- | ||
|''TP53''<br /> | |''TP53''<br /> | ||
|The majority are missense mutations located in exon 7, exon 8, exon 6, and exon 5. Less frequent frameshift mutations in exon 4 and 7 have been described<ref name=":6" />. In general are predicted to be loss of function (LOF) mutations. | |The majority are missense mutations located in exon 7, exon 8, exon 6, and exon 5. Less frequent frameshift mutations in exon 4 and 7 have been described<ref name=":6" />. In general are predicted to be loss of function (LOF) mutations. | ||
|Tumor Supressor Gene | |Tumor Supressor Gene | ||
|Common (>90%) | |Common (>90%) | ||
|No established significance | |No established significance | ||
|No | |No | ||
|<span class="blue-text">EXAMPLE:</span> Exons 18, 19, and 21 mutations are targetable for therapy. Exon 20 T790M variants cause resistance to first generation TKI therapy and are targetable by second and third generation TKIs (add references). | |<span class="blue-text">EXAMPLE:</span> Exons 18, 19, and 21 mutations are targetable for therapy. Exon 20 T790M variants cause resistance to first generation TKI therapy and are targetable by second and third generation TKIs (add references). | ||